Journal of Drug Targeting最新文献_第5页

Decoding the complex web: Cellular and molecular interactions in the lung tumor microenvironment. 解码复杂的网络：肺肿瘤微环境中的细胞和分子相互作用。

IF 4.3 4区医学

Journal of Drug Targeting Pub Date : 2024-12-21 DOI: 10.1080/1061186X.2024.2445772

Bahjat Saeed Issa, Ayat Hussein Adhab, Morug Salih Mahdi, Ashishkumar Kyada, Subbulakshmi Ganesan, Deepak Bhanot, K Satyam Naidu, Sharnjeet Kaur, Aseel Salah Mansoor, Usama Kadem Radi, Nasr Saadoun Abd, Muthena Kariem

{"title":"Decoding the complex web: Cellular and molecular interactions in the lung tumor microenvironment.","authors":"Bahjat Saeed Issa, Ayat Hussein Adhab, Morug Salih Mahdi, Ashishkumar Kyada, Subbulakshmi Ganesan, Deepak Bhanot, K Satyam Naidu, Sharnjeet Kaur, Aseel Salah Mansoor, Usama Kadem Radi, Nasr Saadoun Abd, Muthena Kariem","doi":"10.1080/1061186X.2024.2445772","DOIUrl":"https://doi.org/10.1080/1061186X.2024.2445772","url":null,"abstract":"The lung tumor microenvironment (TME) or stroma is a dynamic space of numerous cells and their released molecules. This complicated web regulates tumor progression and resistance to different modalities. Lung cancer cells in conjunction with their stroma liberate a wide range of factors that dampen antitumor attacks by innate immunity cells like natural killer (NK) cells and also adaptive responses by effector T cells. These factors include numerous growth factors, exosomes and epigenetic regulators, and also anti-inflammatory cytokines. Understanding the intricate interactions between tumor cells and various elements within the lung TME, such as immune and stromal cells can help provide novel strategies for better management and treatment of lung malignancies. The current article discusses the complex network of cells and signaling molecules, which mediate communications in lung TME. By elucidating these multifaceted interactions, we aim to provide insights into potential therapeutic targets and strategies for lung cancer treatment.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1-44"},"PeriodicalIF":4.3,"publicationDate":"2024-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142870843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Isoform-specific vs. isoform-universal drug targeting: a new targeting paradigm illustrated by new anti-ICAM-1 antibodies. 亚型特异性与亚型通用药物靶向：新的抗icam -1抗体说明的新的靶向范式。

IF 4.3 4区医学

Journal of Drug Targeting Pub Date : 2024-12-17 DOI: 10.1080/1061186X.2024.2438884

Marco Vigo, Marina Placci, Silvia Muro

{"title":"Isoform-specific vs. isoform-universal drug targeting: a new targeting paradigm illustrated by new anti-ICAM-1 antibodies.","authors":"Marco Vigo, Marina Placci, Silvia Muro","doi":"10.1080/1061186X.2024.2438884","DOIUrl":"10.1080/1061186X.2024.2438884","url":null,"abstract":"Drug targeting can be achieved by coupling drugs or their carriers to affinity molecules, mostly antibodies (Abs), which recognise specific protein targets. However, most proteins are not expressed in an exclusive configuration but as various isoforms. Hence, selected targeting molecules may fail to target with enough efficiency in clinical trials, which is overlooked. We illustrate this by targeting intercellular adhesion molecule 1 (ICAM-1), a cell-surface protein overexpressed in many pathologies. Most ICAM-1 targeting studies used Ab R6.5, which binds ICAM-1 domain 2 (D2). Yet, literature and our data show that D2 is frequently absent among ICAM-1 isoforms. We thus produced a battery of five new Abs (B4, B6, B11, C12 and G2) and tested their ability to recognise both full-length and -D2 ICAM-1. In solution, all Abs recognised both ICAM-1 forms (from 5.3 × 1011 to 4.2 × 1012 sum intensity/well). Coating them on nanocarriers (NCs) rendered G2 specific against -D2 ICAM-1 (4.2 × 106 NCs/well) while other Abs kept their dual recognition (from 6.4 × 106 to 2.2 × 107 NCs/well). All Abs induced NC intracellular uptake in respective cells (from 42% to 85%) and displayed good cross-species reactivity (from 4.4 × 1011 to 2.6 × 1012 sum intensity/well). These Abs represent valuable tools to target ICAM-1 and illustrate a new targeting paradigm that may improve classical strategies.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1-13"},"PeriodicalIF":4.3,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142785824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

siRNA targeting PARP-1 alleviates diabetic peripheral neuropathy in a streptozotocin-induced rat model. 靶向 PARP-1 的 siRNA 可缓解链脲佐菌素诱导的大鼠模型中的糖尿病周围神经病变

IF 4.3 4区医学

Journal of Drug Targeting Pub Date : 2024-12-16 DOI: 10.1080/1061186X.2024.2431316

Moqbel Ali Moqbel Redhwan, Hariprasad M G, Suman Samaddar, Duaa Bafail, Sumaia Abdulbari Ahmed Ali Hard, Sourav Guha, Apurwa Dhavale

{"title":"siRNA targeting PARP-1 alleviates diabetic peripheral neuropathy in a streptozotocin-induced rat model.","authors":"Moqbel Ali Moqbel Redhwan, Hariprasad M G, Suman Samaddar, Duaa Bafail, Sumaia Abdulbari Ahmed Ali Hard, Sourav Guha, Apurwa Dhavale","doi":"10.1080/1061186X.2024.2431316","DOIUrl":"10.1080/1061186X.2024.2431316","url":null,"abstract":"Diabetic peripheral neuropathy (DPN) is a debilitating complication of diabetes mellitus, affecting nearly 50% of diabetic patients and leading to chronic pain, numbness and progressive sensory and motor function loss. This study investigates the potential of siRNA-mediated silencing of poly(ADP-ribose) polymerase 1 (PARP1) to alleviate DPN in a rat model. PARP1 overactivation, driven by hyperglycaemia-induced oxidative stress, exacerbates neuronal damage in DPN. Using chitosan nanoparticles (ChNPs) to deliver PARP1-targeting siRNA intrathecally in diabetic rats induced with streptozotocin (STZ) 55 mg/kg intraperitoneally, we conducted behavioural and physiological assessments, including Sciatic Functional Index (SFI), motor nerve conduction velocity (MNCV), grip strength and pain sensitivity tests, alongside qRT-PCR analyses, to evaluate therapeutic outcomes. Our findings indicate statistically significant improvements, with siRNA ChNPs-mediated PARP1 silencing alleviating neuropathic symptoms in DPN rats (p < .001 for SFI and MNCV improvements). Biochemical analyses revealed reductions in oxidative stress markers, such as MDA, and increased antioxidant levels, including GSH, CAT and SOD (p < .001). Pro-inflammatory cytokines and apoptotic markers, including NF-κB, IL6, IL1β, TNFa, TGF-β, CAS3, CAS9, BAK and BAX, also showed significant reductions (p < .01), confirming the neuroprotective effects of PARP1 inhibition. These results highlight the potential of siRNA-based therapies targeting PARP1 as a promising therapeutic approach for DPN, paving the way for future research with clinical applications.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1-12"},"PeriodicalIF":4.3,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142675065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mitochondrial-targeted liposome-based drug delivery - therapeutic potential and challenges. 线粒体靶向脂质体给药-治疗潜力和挑战。

IF 4.3 4区医学

Journal of Drug Targeting Pub Date : 2024-12-08 DOI: 10.1080/1061186X.2024.2437440

Lissette Sanchez-Aranguren, Mohamad Anas Al Tahan, Muhammad Uppal, Parag Juvale, Mandeep Kaur Marwah

{"title":"Mitochondrial-targeted liposome-based drug delivery - therapeutic potential and challenges.","authors":"Lissette Sanchez-Aranguren, Mohamad Anas Al Tahan, Muhammad Uppal, Parag Juvale, Mandeep Kaur Marwah","doi":"10.1080/1061186X.2024.2437440","DOIUrl":"10.1080/1061186X.2024.2437440","url":null,"abstract":"Liposomes, as nanocarriers for therapeutics, are a prominent focus in translational medicine. Given their biocompatibility, liposomes are suitable drug delivery systems rendering highly efficient therapeutic outcomes with minimal off-site toxicity. In different scenarios of human disease, it is essential not only to maintain therapeutic drug levels but also to target them to the appropriate intracellular compartment. Mitochondria regulate cellular signalling, calcium balance, and energy production, playing a crucial role in various human diseases. The notion of focusing on mitochondria for targeted drug delivery was proposed several decades ago, yet the practical application of this idea and its translation to clinical use is still in development. Mitochondrial-targeted liposomes offer an alternative to standard drug delivery systems, potentially reducing off-target interactions, side effects, and drug dosage or frequency. To advance this field, it is imperative to integrate various disciplines such as efficient chemical design, pharmacology, pharmaceutics, and cell biology. This review summarises scientific advances in the design, development and characterisation of novel liposome-based drug delivery systems targeting the mitochondria while revisiting their translational potential.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1-12"},"PeriodicalIF":4.3,"publicationDate":"2024-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142769220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Synergistic cancer treatment using porphyrin-based metal-organic Frameworks for photodynamic and photothermal therapy. 利用卟啉基金属有机框架进行光动力和光热治疗的协同癌症治疗。

IF 4.3 4区医学

Journal of Drug Targeting Pub Date : 2024-12-02 DOI: 10.1080/1061186X.2024.2433551

Mahsa Akbari Oryani, Mojtaba Tarin, Leila Rahnama Araghi, Farangis Rastin, Hossein Javid, Alireza Hashemzadeh, Mehdi Karimi-Shahri

{"title":"Synergistic cancer treatment using porphyrin-based metal-organic Frameworks for photodynamic and photothermal therapy.","authors":"Mahsa Akbari Oryani, Mojtaba Tarin, Leila Rahnama Araghi, Farangis Rastin, Hossein Javid, Alireza Hashemzadeh, Mehdi Karimi-Shahri","doi":"10.1080/1061186X.2024.2433551","DOIUrl":"https://doi.org/10.1080/1061186X.2024.2433551","url":null,"abstract":"Recent advancements in multifunctional nanomaterials for cancer therapy have highlighted porphyrin-based metal-organic frameworks (MOFs) as promising candidates due to their unique properties and versatile applications. This overview focuses on the use of porphyrin-based MOFs for combined photodynamic therapy (PDT) and photothermal therapy (PTT) in cancer treatment. Porphyrin-based MOFs offer high porosity, tuneable structures, and excellent stability, making them ideal for drug delivery and therapeutic applications. The incorporation of porphyrin molecules into the MOF framework enhances light absorption and energy transfer, leading to improved photodynamic and photothermal effects. Additionally, the porosity of MOFs allows for the encapsulation of therapeutic agents, further enhancing efficacy. In PDT, porphyrin-based MOFs generate reactive oxygen species (ROS) upon light activation, destroying cancer cells. The photothermal properties enable the conversion of light energy into heat, resulting in localised hyperthermia and tumour ablation. The combination of PDT and PTT in a single platform offers synergistic effects, leading to better therapeutic outcomes, reduced side effects, and improved selectivity. This dual-modal treatment strategy provides precise spatiotemporal control over the treatment process, paving the way for next-generation therapeutics with enhanced efficacy and reduced side effects. Further research and optimisation are needed for clinical applications.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1-19"},"PeriodicalIF":4.3,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142769227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Artificial intelligence-based molecular property prediction of photosensitising effects of drugs. 基于人工智能的药物光敏效应分子性质预测。

IF 4.3 4区医学

Journal of Drug Targeting Pub Date : 2024-12-02 DOI: 10.1080/1061186X.2024.2434911

Amun G Hofmann, Benedikt Weber, Sally Ibbotson, Asan Agibetov

{"title":"Artificial intelligence-based molecular property prediction of photosensitising effects of drugs.","authors":"Amun G Hofmann, Benedikt Weber, Sally Ibbotson, Asan Agibetov","doi":"10.1080/1061186X.2024.2434911","DOIUrl":"https://doi.org/10.1080/1061186X.2024.2434911","url":null,"abstract":"Drug-induced photosensitivity is a potential adverse event of many drugs and chemicals used across a wide range of specialties in clinical medicine. In the present study, we investigated the feasibility of predicting the photosensitising effects of drugs and chemical compounds via state-of-the-art artificial intelligence-based workflows. A dataset of 2200 drugs was used to train three distinct models (logistic regression, XGBoost and a deep learning model (Chemprop)) to predict photosensitising attributes. Labels were obtained from a list of previously published photosensitisers by string matching and manual validation. External evaluation of the different models was performed using the tox21 dataset. ROC-AUC ranged between 0.8939 (Chemprop) and 0.9525 (XGBoost) during training, while in the test partition it ranged between 0.7785 (Chemprop) and 0.7927 (XGBoost). Analysis of the top 200 compounds of each model resulted in 55 overlapping molecules in the external validation set. Prediction scores in fluoroquinolones within this subset corresponded well with culprit substructures such as fluorinated aryl halides suspected of mediating photosensitising effects. All three models appeared capable of predicting photosensitising effects of chemical compounds. However, compared to the simpler model, the complex models appeared to be more confident in their predictions as exhibited by their distribution of prediction scores.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1-6"},"PeriodicalIF":4.3,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142769291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Selection of LRP1 ligand phage-displayed single domain antibody that transmigrates BBB. LRP1配体噬菌体显示的血脑屏障单结构域抗体的选择。

IF 4.3 4区医学

Journal of Drug Targeting Pub Date : 2024-12-02 DOI: 10.1080/1061186X.2024.2434908

Viana Manrique-Suárez, Bryan A Mangui Catota, Frank Camacho Casanova, Nery A Jara Mendoza, Maria A Contreras Vera, Rafael Maura Pérez, Fátima Reyes López, Roberto Toledo Alonso, Pablo Ignacio Castro Henriquez, Oliberto Sánchez Ramos

{"title":"Selection of LRP1 ligand phage-displayed single domain antibody that transmigrates BBB.","authors":"Viana Manrique-Suárez, Bryan A Mangui Catota, Frank Camacho Casanova, Nery A Jara Mendoza, Maria A Contreras Vera, Rafael Maura Pérez, Fátima Reyes López, Roberto Toledo Alonso, Pablo Ignacio Castro Henriquez, Oliberto Sánchez Ramos","doi":"10.1080/1061186X.2024.2434908","DOIUrl":"https://doi.org/10.1080/1061186X.2024.2434908","url":null,"abstract":"Effective drug delivery to the central nervous system (CNS) remains a challenge due to the blood-brain barrier (BBB). Macromolecules such as proteins and peptides are unable to cross BBB and have poor therapeutic efficacy due to little or no drug distribution. A promising alternative is the conjugation of a drug to a shuttle molecule that can reach the CNS via receptor-mediated transcytosis (RMT). Several receptors have been described for RMT, such as low-density lipoprotein receptor-related protein 1 (LRP1). We used phage display technology combined with an in vitro BBB model to identify LRP1 ligands. A single domain antibody (dAb) library was used to enrich for species that selectively bind to immobilised LRP1 ligand. We obtained a novel nanobody, dAb D11, that selectively binds to LRP1 receptor and mediates in vitro internalisation of phage particles in brain endothelial cells, with a dissociation constant Kd of 183.1 ± 85.8 nM. The high permeability of D11 was demonstrated by an in vivo biodistribution assay in mice. We discovered D11, the first LRP1 binding dAb with BBB permeability. Our findings will contribute to the development of RMT-based drugs for the treatment of CNS diseases.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1-10"},"PeriodicalIF":4.3,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142769223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Artificial intelligence in nanotechnology for treatment of diseases. 人工智能纳米技术治疗疾病。

IF 4.3 4区医学

Journal of Drug Targeting Pub Date : 2024-12-01 Epub Date: 2024-08-27 DOI: 10.1080/1061186X.2024.2393417

Soroush Heydari, Niloofar Masoumi, Erfan Esmaeeli, Seyed Mohammad Ayyoubzadeh, Fatemeh Ghorbani-Bidkorpeh, Mahnaz Ahmadi

{"title":"Artificial intelligence in nanotechnology for treatment of diseases.","authors":"Soroush Heydari, Niloofar Masoumi, Erfan Esmaeeli, Seyed Mohammad Ayyoubzadeh, Fatemeh Ghorbani-Bidkorpeh, Mahnaz Ahmadi","doi":"10.1080/1061186X.2024.2393417","DOIUrl":"10.1080/1061186X.2024.2393417","url":null,"abstract":"Nano-based drug delivery systems (DDSs) have demonstrated the ability to address challenges posed by therapeutic agents, enhancing drug efficiency and reducing side effects. Various nanoparticles (NPs) are utilised as DDSs with unique characteristics, leading to diverse applications across different diseases. However, the complexity, cost and time-consuming nature of laboratory processes, the large volume of data, and the challenges in data analysis have prompted the integration of artificial intelligence (AI) tools. AI has been employed in designing, characterising and manufacturing drug delivery nanosystems, as well as in predicting treatment efficiency. AI's potential to personalise drug delivery based on individual patient factors, optimise formulation design and predict drug properties has been highlighted. By leveraging AI and large datasets, developing safe and effective DDSs can be accelerated, ultimately improving patient outcomes and advancing pharmaceutical sciences. This review article investigates the role of AI in the development of nano-DDSs, with a focus on their therapeutic applications. The use of AI in DDSs has the potential to revolutionise treatment optimisation and improve patient care.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1247-1266"},"PeriodicalIF":4.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142000031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Long-term residence and efficacy of adenovirus-mimetic nanoparticles in renal target tissue. 仿腺病毒纳米粒子在肾脏靶组织中的长期驻留和疗效。

IF 4.3 4区医学

Journal of Drug Targeting Pub Date : 2024-12-01 Epub Date: 2024-08-22 DOI: 10.1080/1061186X.2024.2390628

Melanie Walter, Hannah Weißbach, Florian Gembardt, Sagor Halder, Kathrin Schorr, Daniel Fleischmann, Vladimir Todorov, Christian Hugo, Achim Goepferich

{"title":"Long-term residence and efficacy of adenovirus-mimetic nanoparticles in renal target tissue.","authors":"Melanie Walter, Hannah Weißbach, Florian Gembardt, Sagor Halder, Kathrin Schorr, Daniel Fleischmann, Vladimir Todorov, Christian Hugo, Achim Goepferich","doi":"10.1080/1061186X.2024.2390628","DOIUrl":"10.1080/1061186X.2024.2390628","url":null,"abstract":"A major shortcoming in the treatment of mesangial cell-associated diseases such as IgA nephropathy, diabetic nephropathy, or lupus nephritis, which frequently progress to end-stage renal disease, is poor drug availability in the glomerular mesangium. Drug delivery via active targeting of nanoparticles, using ligands attached to the particle surface for target cell recognition to increase the biodistribution to the mesangium, is a promising strategy to overcome this hurdle. However, although several glomerular tissue targeting approaches have been described, so far no study has demonstrated the particles' ability to deliver sufficient drug amounts combined with an appropriate nanoparticle target retention time to trigger relevant biological effects in the mesangium. In our study, we encapsulated erastin, a ferroptosis-inducing model compound, into adenovirus-mimetic, mesangial cell-targeting nanoparticles, enabling the direct visualisation of biological effects through ferroptosis-dependent histological changes. By intravital microscopy and analysis of histological sections, we were not only able to localise the injected particles over 10 days within the target cells but also to demonstrate biological activity in the renal glomeruli. In conclusion, we have characterised adenovirus-mimetic nanoparticles as a highly suitable drug delivery platform for the treatment of mesangial cell-associated diseases and additionally provided the basis for a potential renal disease model.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1320-1332"},"PeriodicalIF":4.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142017636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Factors of faecal microbiota transplantation applied to cancer management. 将粪便微生物群移植应用于癌症治疗的因素。

IF 4.5 4区医学

Journal of Drug Targeting Pub Date : 2024-12-01 Epub Date: 2024-02-01 DOI: 10.1080/1061186X.2023.2299724

Yi-Huang Liu, Juan Chen, Xiang Chen, Hong Liu

引用次数: 0